Merck (MRK) Inventory Average (2009 - 2026)
Merck (MRK) reported Inventory Average of $6.6 billion for Q1 2026, up 6.76% year-over-year from $6.2 billion in Q1 2025, and little changed quarter-over-quarter from $6.6 billion in Q4 2025.
Merck (MRK) Inventory Average (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Inventory Average data on file, last reported at $6.6 billion in Q1 2026.
- Inventory Average for Q1 2026 came in at $6.6 billion, up 6.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.6 billion (up 6.76% YoY), and the FY2025 annual result was $6.4 billion, up 2.41% from the prior year.
- Inventory Average steadied at $6.6 billion in Q1 2026 per MRK's latest filing, from $6.6 billion in the prior quarter.
- Over five years, Inventory Average peaked at $6.6 billion in Q1 2026 and troughed at $5.6 billion in Q3 2022.
- A 5-year average of $6.2 billion and a median of $6.2 billion in 2024 frame the typical range for Inventory Average.
- The sharpest annual moves came in 2022 and 2024: Inventory Average fell 4.97% in 2022, then increased 10.06% in 2024.
- A 5-year view of Inventory Average shows it stood at $5.8 billion in 2022, then advanced by 8.36% to $6.2 billion in 2023, then fell by 1.09% to $6.2 billion in 2024, then rose by 6.06% to $6.6 billion in 2025, then climbed by 0.27% to $6.6 billion in 2026.
- Business Quant data shows MRK's Inventory Average at $6.6 billion in Q1 2026, $6.6 billion in Q4 2025, and $6.5 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 8.09 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 14.14 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 14.39 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 5.00 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 6.57 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 6.21 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 1.84 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 10.66 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.72 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.57 Bn |
| Dec 31, 2025 | 6.55 Bn |
| Sep 30, 2025 | 6.52 Bn |
| Jun 30, 2025 | 6.40 Bn |
| Mar 31, 2025 | 6.15 Bn |
| Dec 31, 2024 | 6.18 Bn |
| Sep 30, 2024 | 6.36 Bn |
| Jun 30, 2024 | 6.49 Bn |
| Mar 31, 2024 | 6.43 Bn |
| Dec 31, 2023 | 6.24 Bn |
| Sep 30, 2023 | 6.03 Bn |
| Jun 30, 2023 | 5.90 Bn |
| Mar 31, 2023 | 5.89 Bn |
| Dec 31, 2022 | 5.76 Bn |
| Sep 30, 2022 | 5.57 Bn |
| Jun 30, 2022 | 5.65 Bn |
| Mar 31, 2022 | 5.86 Bn |
| Dec 31, 2021 | 5.78 Bn |
| Sep 30, 2021 | 5.55 Bn |
| Jun 30, 2021 | 5.95 Bn |